5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!
Open Access
- 1 August 2005
- Vol. 54 (8) , 1056-1057
- https://doi.org/10.1136/gut.2004.063545
Abstract
There is growing evidence that 5-HT3 receptor blockade will benefit patients with fatigue. Further research is needed to determine the mechanism underlying this widespread clinically important symptom and therapies may be derived from targeting the 5-HT system.Keywords
This publication has 23 references indexed in Scilit:
- Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled studyGut, 2005
- Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635Biological Psychiatry, 2005
- A cytoplasmic region determines single-channel conductance in 5-HT3 receptorsNature, 2003
- The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor SubunitPublished by Elsevier ,1999
- Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapyThe Lancet, 1999
- Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetronEuropean Journal of Gastroenterology & Hepatology, 1998
- Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetronPain, 1995
- Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrainNeuropharmacology, 1993
- Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the ratNeuropharmacology, 1990
- Identification and Characterisation of 5‐Hydroxytryptamine3 Recognition Sites in Human Brain TissueJournal of Neurochemistry, 1989